Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains - Wikidata - wikimedia - TriplyDB

Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains

Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains

http://www.wikidata.org/entity/Q27685477

about

Modulation of Protein-Protein Interactions for the Development of Novel Therapeutics Acetyl-lysine Binding Site of Bromodomain-Containing Protein 4 (BRD4) Interacts with Diverse Kinase Inhibitors Targeting bromodomains: epigenetic readers of lysine acetylation Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains Targeting BET bromodomains for cancer treatment Segmental Isotope Labelling of an Individual Bromodomain of a Tandem Domain BRD4 Using Sortase A Drug Discovery Targeting Bromodomain-Containing Protein 4.Privileged diazepine compounds and their emergence as bromodomain inhibitors.Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma.Evolution of a strategy for preparing bioactive small molecules by sequential multicomponent assembly processes, cyclizations, and diversification Small-molecule inhibitors of protein-protein interactions: progressing toward the reality.Epigenetic drugs against cancer: an evolving landscape.Inducible in vivo silencing of Brd4 identifies potential toxicities of sustained BET protein inhibition Molecularly targeted therapies in non-small-cell lung cancer annual update 2014 Bromodomain inhibitors regulate the C9ORF72 locus in ALS Targeting protein-protein interactions in hematologic malignancies: still a challenge or a great opportunity for future therapies?Impressive Response to Dose-Dense Chemotherapy in a Patient with NUT Midline Carcinoma.The Bromodomain protein BRD4 controls HOTAIR, a long noncoding RNA essential for glioblastoma proliferation.BET Bromodomain Proteins Brd2, Brd3 and Brd4 Selectively Regulate Metabolic Pathways in the Pancreatic β-Cell.Small molecules, big targets: drug discovery faces the protein-protein interaction challenge.Mapping the chemical chromatin reactivation landscape identifies BRD4-TAF1 cross-talk.BET inhibition as a new strategy for the treatment of gastric cancer.Potent and selective bivalent inhibitors of BET bromodomains.CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer BET protein Brd4 activates transcription in neurons and BET inhibitor Jq1 blocks memory in mice Structure-Guided Design of IACS-9571, a Selective High-Affinity Dual TRIM24-BRPF1 Bromodomain Inhibitor.ERK5 kinase activity is dispensable for cellular immune response and proliferation.Comparative drug screening in NUT midline carcinoma.Phenotypic screening and fragment-based approaches to the discovery of small-molecule bromodomain ligands.Bromodomains and their pharmacological inhibitors.Epigenetic pathway targets for the treatment of disease: accelerating progress in the development of pharmacological tools: IUPHAR Review 11.MLL leukemia and future treatment strategies.Selective Inhibition of CBX6: A Methyllysine Reader Protein in the Polycomb Family Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence.Inhibitors of emerging epigenetic targets for cancer therapy: a patent review (2010-2014).Discovery and Characterization of GSK2801, a Selective Chemical Probe for the Bromodomains BAZ2A and BAZ2B.Progress in the Development of non-BET Bromodomain Chemical Probes.BET Bromodomain Inhibitors with One-Step Synthesis Discovered from Virtual Screen.Transcriptional Elongation of HSV Immediate Early Genes by the Super Elongation Complex Drives Lytic Infection and Reactivation from Latency.Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression.

P2860

Q26775356-4A0F174D-6EF9-41C1-B181-A4FC688F6499 Q27681896-517D7030-4AF2-4FC2-BED9-E160FAF0DB4B Q28238635-50D3AE30-375D-4B77-BF22-5239D7897B99 Q28242369-3B0340CD-267D-4841-90AE-4F50AA15AD29 Q28263519-75E6AE59-2F94-440E-A30C-70B588BCEA52 Q28551713-D50DC968-6ED8-4F54-98F3-729F10CD577A Q30352390-253AF1D5-C900-4592-A12B-39FFB4C28176 Q33671341-DF72713F-1E95-4280-AE5B-17486E21A4AA Q33756997-8B6043DD-9776-4050-8D69-B6B64BD12E3D Q34207033-D62439E6-D5E5-40B8-BB18-1EF1A4E624FB Q34263719-DDCF7B32-0F28-4733-9CE0-8641B86C1410 Q34431964-2D8F740A-6751-4C3C-92E3-98A24DA92930 Q34522818-187514CE-1EC0-4551-B5BE-CF5240A1ECAF Q35136424-AD50295D-AD7E-41F0-860C-2B1D14CB8055 Q35670978-E503E39C-B1EA-4788-AF50-552FC1073E64 Q35687836-0A9D7DE9-C960-47E3-BEEC-80D86E7DEA3E Q35821531-9E2CC309-2534-4DA5-A88A-2A7122618D63 Q35846001-6851BB44-2812-4FA6-BEF4-C346AF88521F Q35967957-C2DA6D40-915C-4598-AA21-0260359C5914 Q35981250-9100595E-DF45-4B59-88BB-BCAB6913C466 Q36012341-08EECE7E-E2EA-46E3-B573-1052FF14560B Q36040347-9AD11BA6-BFB0-4253-A098-03FE05ACC92F Q36172945-E53790FA-2B86-4326-BBFB-83CB7E5CB1ED Q36515055-F6A108B7-F2B7-4FB0-B845-E9BC1B86E45B Q36575895-B92684DE-BC3F-4ED5-A045-644FA7576621 Q36586506-AA4D0175-0D5A-4EAE-9D7E-99242CFB6C42 Q37369392-11419DCD-DBC8-4526-94FD-857B201CB534 Q37632187-231FB2DF-ECF5-4EC1-BF48-1CD3229C7816 Q38182138-6A1A0BB3-F5FC-4B6D-8175-5E2052122D86 Q38185355-59CA4D3B-6242-4480-96D7-CD2BF300154F Q38233723-AE6ACAC4-5DAE-481C-B8B1-9794E9A1EFBB Q38367735-ED50F17E-7EB0-4E60-86B4-2E8C647B27A4 Q38434032-E395407A-C83D-45BC-8865-06D3FFFA4F51 Q38542092-9B9A17D6-80BD-4EA8-988E-119D6326CA10 Q38547122-76B49CF4-3957-48D0-996B-0AAC13660661 Q38668661-8A615505-C420-47DB-8F00-206BF15B87B2 Q38691377-829DF980-0D66-4280-BD46-274E3DBFBD6F Q38702568-789A1118-045F-4A45-B642-9A5212AA231A Q38707836-203F0AA8-4F71-4147-A85A-08E784D2D708 Q38710711-43BA67A2-D126-4F1A-A755-0F87CD842294

P2860

Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains

http://www.wikidata.org/entity/Q27685477

description

2013 nî lūn-bûn

@nan

2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

name

Discovery of epigenetic regula ...... ibitor of the BET bromodomains

@ast

Discovery of epigenetic regula ...... ibitor of the BET bromodomains

@en

Discovery of epigenetic regula ...... ibitor of the BET bromodomains

@nl

type

label

Discovery of epigenetic regula ...... ibitor of the BET bromodomains

@ast

Discovery of epigenetic regula ...... ibitor of the BET bromodomains

@en

Discovery of epigenetic regula ...... ibitor of the BET bromodomains

@nl

prefLabel

Discovery of epigenetic regula ...... ibitor of the BET bromodomains

@ast

Discovery of epigenetic regula ...... ibitor of the BET bromodomains

@en

Discovery of epigenetic regula ...... ibitor of the BET bromodomains

@nl

P1433

Q27685477-52D384FB-05CC-45CD-BEBF-EE984B73E5AA

P1476

Q27685477-84821E4A-A449-4B05-AF85-4A7323F676EA

P2093

Q27685477-0117C94B-600C-498B-99E0-19857FAE0670

Q27685477-0A04A0FD-B652-4DF9-8954-C66E6ED981AE

Q27685477-0E5D9927-A5D7-46D4-A326-A559CA69DACC

Q27685477-258C5F09-4902-44C5-8579-5EF9417C4121

Q27685477-32D80746-2A2E-4B59-9A78-72F226456A65

Q27685477-389F3D4F-1358-41CD-AD4E-90FD90A60BE1

Q27685477-3BF33842-0166-45B5-8EA8-6D9E2A2E8C83

Q27685477-525EC603-03C1-4CEA-A560-054D4531812F

Q27685477-553AE5F9-D06C-41FA-A499-B63AEA1DA0AB

Q27685477-57E1B3B5-18F4-476C-A6EF-108C599F75EA

P304

Q27685477-222DA48A-C22B-498D-91DE-067C7B184EEB

P31

Q27685477-F454CF70-4B27-481E-9E79-97F37AE62F0D

P3181

Q27685477-E68811B0-564C-48B7-B291-85C33D567B15

P356

Q27685477-15CA849E-C9EF-4A69-8EE0-A28DCCCE2F63

P407

Q27685477-F5AEFAF8-947D-456C-92CF-3DEECA24FBAD

P433

Q27685477-674E46B7-D921-40C0-B0AE-A57E8D1FB4DB

P478

Q27685477-3EF01692-1608-491B-A499-605906B95ED2

P50

Q27685477-9EA72C5C-0431-4DCA-B37D-8DF9E960C008

P577

Q27685477-18381C72-877A-4B80-9DF0-B98A18831779

P698

Q27685477-F22DA66E-7AB8-454E-A36D-1011295CA578

P3181

P356

P1433

Journal of Medicinal Chemistry

P1476

Discovery of epigenetic regula ...... ibitor of the BET bromodomains

@en

P2093

Alain Daugan

http://www.w3.org/2001/XMLSchema#string

Andrea C Haynes

http://www.w3.org/2001/XMLSchema#string

Antonia Lewis

http://www.w3.org/2001/XMLSchema#string

Catherine A Clément

http://www.w3.org/2001/XMLSchema#string

Chun-wa Chung

http://www.w3.org/2001/XMLSchema#string

Edwige Nicodème

http://www.w3.org/2001/XMLSchema#string

Iain J Uings

http://www.w3.org/2001/XMLSchema#string

Jacqueline E Mordaunt

http://www.w3.org/2001/XMLSchema#string

Jason Witherington

http://www.w3.org/2001/XMLSchema#string

Jean-Marie Brusq

http://www.w3.org/2001/XMLSchema#string

P304

7501-15

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4806189

http://www.w3.org/2001/XMLSchema#string

P356

10.1021/JM401088K

http://www.w3.org/2001/XMLSchema#string

P407

P433

19

http://www.w3.org/2001/XMLSchema#string

P478

56

http://www.w3.org/2001/XMLSchema#string

P50

Olivier Mirguet

P577

2013-10-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24015967

http://www.w3.org/2001/XMLSchema#string